Abstract
Peripheral vertigo is often accompanied by other symptoms such as neck/shoulder stiffness and headache. To achieve higher patient satisfaction, treatment of the accompanying symptoms is also required in addition to treating the vertigo. The present study was designed to compare the efficacy of kallidinogenase (150U/day) and adenosine triphosphate disodium (ATP, 3g/day) in treating vertigo as well as the accompanying symptoms. These agents were administered orally for 4 weeks to 40 patients with peripheral vertigo, and the VAS (visual analogue scale) and a questionnaire were used to measure the efficacy. In the kallidinogenase treatment group, VAS scores for vertigo, disequilibrium, headache, dull headache, and tinnitus improved significantly, and the questionnaire survey revealed significant alleviation of vertigo and headache. In the ATP treatment group, VAS scores for vertigo and disequilibrium improved significantly, accompanied by significant alleviation of vertigo and significant shortening of the duration of vertigo. We conclude that kallidinogenase is as effective as, or even better than, ATP in the treatment of vertiginous patients with accompanying symptoms.
